Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis

Cold Spring Harbor Perspectives in Medicine

Volumn 5, Issue 9, 2015, Pages

  Seung, Kwonjune J ^a,b,c   Keshavjee, Salmaan ^a,b,c   Rich, Michael L ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c PARTNERS IN HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; BEDAQUILINE; CAPREOMYCIN; CYCLOSERINE; DELAMANID; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; CHILDHOOD DISEASE; COMMUNITY; DEPRESSION; DRUG MONITORING; DRUG SAFETY; ELECTROLYTE DISTURBANCE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FANCONI RENOTUBULAR SYNDROME; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEALTH CARE FACILITY; HEALTH CARE SYSTEM; HEARING IMPAIRMENT; HOME CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHYROIDISM; LUNG RESECTION; LYMPH NODE BIOPSY; LYMPHADENITIS; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; NAUSEA; NEPHROTOXICITY; OTOTOXICITY; PATIENT CARE; PATIENT COMPLIANCE; PATIENT COUNSELING; PREGNANT WOMAN; PSYCHOSIS; RISK FACTOR; SOCIOECONOMICS; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOUS MENINGITIS; TUBERCULOUS OSTEOMYELITIS; TUBERCULOUS SPONDYLITIS; VOMITING; CHILD; COMBINATION DRUG THERAPY; COMMUNITY CARE; COMPLICATION; DRUG ADMINISTRATION; DRUG DESIGN; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HEALTH; ORGANIZATION AND MANAGEMENT; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; CHILD; COINFECTION; COMMUNITY HEALTH SERVICES; DRUG ADMINISTRATION SCHEDULE; DRUG DESIGN; DRUG THERAPY, COMBINATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; FLUOROQUINOLONES; GLOBAL HEALTH; HIV INFECTIONS; HUMANS; ISONIAZID; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RIFAMPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84940783301     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a017863     Document Type: Article

References (39)

1. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona J, Becerra M, Benedetti A, Burgos M, Centis R, et al. 2012. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: An individual patient data meta-analysis of 9,153 patients. PLoS Med 9: e1001300.
2. Becerra M, Franke MF, Appleton SC, Joseph JK, Bayona J, Atwood SS, Mitnick CD. 2013. Tuberculosis in children exposed at home to multidrug-resistant tuberculosis. Pediatr Infect Dis J 32: 115–119.
3. Cegielski JP. 2010. Extensively drug-resistant tuberculosis: “There must be some kind of way out of here”. Clin Infect Dis 50: S195–S200.
4. Centers for Disease Control and Prevention (CDC). 2013. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR Recomm Rep 62: 1–12.
5. Chavez Pachas AM, Blank R, Fawzi Smith MC, Bayona J, Becerra M, Mitnick CD. 2004. Identifying early treatmentfailure on category I therapy for pulmonary tuberculosis in Lima Ciudad, Peru. Int J Tuberc Lung Dis 8: 52–58.
6. Curry International Tuberculosis Center, California Department of Public Health. 2012. Tuberculosis Drug Information Guide, 2nd ed. Curry International Tuberculosis Center, San Francisco, California.
7. Dye C, Williams BG, Espinal MA, Raviglione MC. 2002. Erasing the world’s slow stain: Strategies to beat multidrug-resistant tuberculosis. Science 295: 2042–2046.
8. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. 1993. The emergence of drug-resistant tuberculosis in New York City. New Engl J Med 328: 521–526.
9. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. 1995. Tuberculosis in New York City—Turning the tide. New Engl J Med 333: 229–233.
10. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368: 1575–1580.
11. Garcia-Prats AJ, Donald PR, Hesseling AC, Schaaf HS. 2013. Second-Line antituberculosis drugs in children: A commissioned review for the World Health Organization 19th Expert Committee on the Selection and Use of Essential Medicines. World Health Organization, Geneva.
12. Gelmanova IY, Keshavjee S, Golubchikova VT, Berezina VI, Strelis AK, Yanova GV, Atwood S, Murray M. 2007. Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: Non-adherence, default and the acquisition of multidrug resistance. Bull World Health Organ 85: 703–711.
13. Johnson JL, Hadad DJ, Boom WH, Daley CL, Peloquin CA, Eisenach KD, Jankus DD, Debanne SM, Charlebois ED, Maciel E, et al. 2006. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 10: 605–612.
14. Keshavjee S, Farmer PE. 2012. Tuberculosis, drug resistance, and the history of modern medicine. New Engl J Med 367: 931–936.
15. Lin H, Shin S, Blaya JA, Zhang Z, Cegielski P, Contreras C, Asencios L, Bonilla C, Bayona J, Paciore CJ, et al. 2011. Assessing spatiotemporal patterns of multidrug-resistant and drug-sensitive tuberculosis in a South American setting. Epidemiol Infect 139: 1784–1793.
16. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcantara F, Sanchez E, Sarria M, Becerra M, Fawzi MC, et al. 2003. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. New Engl J Med 348: 119–128.
17. Mukherjee JS, Rich ML, Socci AR, Joseph JK, Viru´ FA, Shin SS, Furin JJ, Becerra MC, Barry DJ, Kim JY, et al. 2004. Programmes and principles in treatment of multidrugresistant tuberculosis. Lancet 363: 474–481.
18. Partners In Health. 2013. The PIH guide to the medical management of multidrug-resistant tuberculosis, 2nd ed. Partners In Health, Boston.
19. Peloquin CA, Hadad DJ, Molino LP, Palaci M, Boom WH, Dietze R, Johnson JL. 2008. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 52: 852–857.
20. Pomerantz BJ, Cleveland JC, Olson JK, Pomerantz M. 2001. Pulmonary resection for multi-drug resistant tuberculosis. J Thorac Cardiovasc Surg 121: 448–453.
21. Pyle M. 1947. Relative number of resistant tubercle bacilli in sputa of patients before and during treatment with streptomycin. In Proceedings of the staff meetings Mayo Clinic 22: 465–473.
22. Satti H, McLaughlin MM, Seung KJ, Becerra MC, Keshavjee S. 2013. High risk of drug-resistant tuberculosis when first-line therapy fails in a high HIV prevalence setting. Int J Tuberc Lung Dis 17: 100–106.
23. Seung KJ, Rich ML. 2010. Diagnosis and treatment of drugresistant tuberculosis. In Tuberculosis: The essentials, 4th ed. (ed. Raviglione MC), pp. 170–214. Informa Healthcare, New York.
24. Seung KJ, Gelmanova IE, Peremitin GG, Golubchikova VT, Pavlova VE, Sirotkina OB, Yanova GV, Strelis AK. 2004. The effect of initial drug resistance on treatment response and acquired drug resistance during standardized shortcourse chemotherapy for tuberculosis. Clin Infect Dis 39: 1321–1328.
25. Seung KJ, Omatayo DB, Keshavjee S, Furin JJ, Farmer PE, Satti H. 2009. Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. PloS ONE 4: e7186.
26. Shin S, Pasechnikov AD, Gelmanova IY, Peremitin GG, Strelis AK, Mishustin S, Barnashov A, Karpeichik Y, Andreev YG, Golubchikova VT, et al. 2006. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis 10: 402–408.
27. Skrahina A, Hurevich H, Zalutskaya A, Sahalchyk E, Astrauko A, van Gemert W, Hoffner S, Rusovich V, Zignol M. 2012. Alarming levels of drug-resistant tuberculosis in Belarus: Results of a survey in Minsk. Eur Respir J 39: 1425–1431.
28. Somocurcio JG, Sotomayor A, Shin S, Portilla S, Valcarcel M, Guerra D, Furin J. 2007. Surgery for patients with drug-resistant tuberculosis: Report of 121 cases receiving community-based treatment in Lima, Peru. Thorax 62: 416–421.
29. The Sentinel Project for Pediatric Drug-Resistant Tuberculosis. 2012. Management of multidrug-resistant tuberculosisin children: A field guide. The Sentinel Project for Pediatric Drug-Resistant Tuberculosis, Boston.
30. USAID TB CARE II. 2011. Community-based care for drugresistant tuberculosis: A guide for implementers. Partners In Health, Boston.
31. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder HL. 2010. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 182: 684–692.
32. Varaine F, Rich ML. 2013. Tuberculosis: Practical guide for clinicians, nurses, laboratory technicians and medical auxiliaries. Me´decins San Frontie`res and Partners in Health, Paris.
33. Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A, Castro KG, Weyer K. 2007. HIV infection and multidrug-resistant tuberculosis: The perfect storm. J Infect Dis 196: S86–S107.
34. World Health Organization (WHO). 2011a. Guidelines for the programmatic management of drug-resistant tuberculosis, 2011 update. World Health Organization, Geneva.
35. World Health Organization (WHO). 2011b. Policy Statement: Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. World Health Organization, Geneva.
36. World Health Organization (WHO). 2013a. Global tuberculosis report 2013. World Health Organization, Geneva.
37. World Health Organization (WHO). 2013b. Definitions and reporting framework for tuberculosis—2013 revision.
38. World Health Organization, Geneva. World Health Organization (WHO). 2013c. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: Interim policy guidance.World Health Organization, Geneva.
39. Zhao Y, Xu S, Wang L, Chin DP, Wang S, Jiang G, Xia H, Zhou Y, Li Q, Ou X, et al. 2012. National survey of drug-resistant tuberculosis in China. New Engl J Med 366: 2161–2170.